Envista/$NVST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Envista
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
Ticker
$NVST
Sector
Primary listing
NYSE
Employees
12,300
Headquarters
Website
Envista Metrics
BasicAdvanced
$3.5B
67.36
$0.31
1.01
-
Price and volume
Market cap
$3.5B
Beta
1.01
52-week high
$22.68
52-week low
$14.22
Average daily volume
1.9M
Financial strength
Current ratio
2.437
Quick ratio
1.931
Long term debt to equity
49.701
Total debt to equity
50.851
Interest coverage (TTM)
4.86%
Profitability
EBITDA (TTM)
309.9
Gross margin (TTM)
54.79%
Net profit margin (TTM)
2.11%
Operating margin (TTM)
7.44%
Effective tax rate (TTM)
53.54%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
2.14%
Return on equity (TTM)
1.76%
Valuation
Price to earnings (TTM)
67.362
Price to revenue (TTM)
1.412
Price to book
1.12
Price to tangible book (TTM)
33.93
Price to free cash flow (TTM)
13.975
Free cash flow yield (TTM)
7.16%
Free cash flow per share (TTM)
1.503
Growth
Revenue change (TTM)
0.76%
Earnings per share change (TTM)
-104.03%
3-year revenue growth (CAGR)
0.22%
3-year earnings per share growth (CAGR)
-42.99%
What the Analysts think about Envista
Analyst ratings (Buy, Hold, Sell) for Envista stock.
Bulls say / Bears say
Envista’s Q2 sales beat expectations at $682 million, with core sales growth of 5.6% across all segments and regions, including Nobel Biocare in North America (Reuters)
Adjusted EPS surged 136% YoY to $0.26 in Q2 2025, outperforming analyst expectations and showing improved profitability (Reuters)
Management raised full-year 2025 outlook, lifting the core sales growth target to 3–4% (up from 1–3%) and increasing the adjusted EPS forecast to $1.05–$1.15, showing confidence in ongoing momentum (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Envista Financial Performance
Revenues and expenses
Envista Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Envista stock?
Envista (NVST) has a market cap of $3.5B as of September 13, 2025.
What is the P/E ratio for Envista stock?
The price to earnings (P/E) ratio for Envista (NVST) stock is 67.36 as of September 13, 2025.
Does Envista stock pay dividends?
No, Envista (NVST) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Envista dividend payment date?
Envista (NVST) stock does not pay dividends to its shareholders.
What is the beta indicator for Envista?
Envista (NVST) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.